Human Growth Hormone Market Size, Share & Growth Report 2031

Report Description

Human Growth Hormone Market Outlook

The global human growth hormone market size was USD 6.93 billion in 2022 and is projected to reach USD 14.32 billion by 2031, expanding at a CAGR of 8.4 % during the forecast period, 2023–2031. The growth of the market is attributed to the factors such as increasing industry players’ investments in R&D activities, the presence of a strong pipeline, and expanding government initiatives.

Human growth hormone (hGH), also known as somatotropin, is a peptide hormone that is vital for human development, as it stimulates growth, cell reproduction, and cell regeneration. In humans, growth hormone (GH) insufficiency is caused by the failure of pituitary gland to generate enough hGH. In humans, this deficit is addressed by subcutaneous injections of recombinant hGH.

Get Free Sample Report

Growth hormone insufficiency in humans can be caused by a variety of genetic illnesses, including Prader-Willi syndrome and Turner syndrome, which can result in delayed puberty and shorter-than-average height. 

According to data released by the American Academy of Pediatrics, growth hormone insufficiency is a rare illness that affects less than one in 10,000 children in the US. hGH is being abused by bodybuilders and sportsmen as an anti-aging treatment and as a performance-enhancing anabolic substance.

However, according to the USFDA, hGH is a regulated chemical that has not been licensed for anti-aging or performance-enhancing purposes.

International Children's Growth Awareness Day is observed every year by the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a non-profit charitable organization based in the US, to raise awareness about the early detection and treatment of growth hormone disorders in humans, particularly children.

According to UPMC Children's Hospital of Pittsburgh. Knee, hip, or other joint discomfort, allergic reactions, such as redness, swelling, or hives, and increase in the blood sugar levels are all possible adverse effects of GH therapy,

Human Growth Hormone Market Trends, Drivers, Restraints, and Opportunities

• Various government and private organizations initiatives to raise awareness about GH deficiency and human growth hormone treatment are driving the market growth.
• High cost of therapies can hinder the market growth.
• Rapid development of new novel recombinant human growth hormones is estimated to spur the market expansion in the coming years.

Scope of The Human Growth Hormone Market Report

The report on the global human growth hormone market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Human Growth Hormone Market Segment Insights

Growth Hormone Deficiency segment is projected to account for a key market share

Based on applications, the market is segmented into growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader Willi syndrome, small for gestational age, and others. The growth hormone deficiency segment is further divided into adult growth hormone deficiency and pediatric growth hormone deficiency.

The growth hormone deficiency segment is expected to account for a key market share during the forecast period owing to the early detection and treatment of GH deficiency in people, as well as the introduction of new medications into the market.

For instance, Ascendis Pharma A/S gained Orphan Designation from the European Commission (EC) in October 2018 for TransCon hGH, an experimental long-acting GH medication for humans, recommended for the treatment of pediatric GH deficiency.

Similarly, Ferring Pharmaceuticals Inc. got USFDA approval in January 2018 for Zomacton (somatropin), a novel recombinant hGH intended for the treatment of adults with GH insufficiency.

Adult GH deficiency and pediatric GH deficiency are the two types of GH deficiency, with the latter expected to dominate the market during the forecast period due to the growing number of pipeline medications. For instance, in October 2019, Pfizer Inc.

and its partner OPKO Health Inc., stated that their Phase III research of Somatrogon in pre-pubertal children with hGH met its primary endpoint of non-inferiority to daily somatropin.

The Turner syndrome segment is anticipated to expand at a rapid pace during the forecast period owing to increasing public and commercial sector initiatives to raise awareness about early detection and treatment of Turner syndrome.

Every year in February, non-profit organizations such as the Turner Syndrome Support Society in the UK, the Turner Syndrome Society of the US, and the Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" and launch a nationwide campaign to raise awareness about the condition.

Get Free Sample Report

Online pharmacy segment is anticipated to expand at a substantial CAGR

On the basis of distribution channels, the human growth hormone market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. The online pharmacies segment is expected to expand at a rapid pace during the forecast period owing to the increasing penetration of pharmacies in regions such as North America and Europe.

Additionally, growing preference for online pharmacies in emerging economies such as India and China is expected to drive the segment growth. In 2019, the hospital pharmacies segment accounted for a major market share.

According to the Children's Hospital of Philadelphia (CHOP), prescriptions for growth hormone have climbed from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 patients per 10,000 beneficiaries in 2016.

Get Free Sample Report

Human Growth Hormone Market Regional Outlook

Asia Pacific is anticipated to dominate the market

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period. Key companies aim to gain a significant market share in Asia Pacific, especially in Japan and China.

For instance, in March 2017, Novo Nordisk A/S, a Denmark-based pharmaceutical company, began a phase III clinical trial in Japan for its hGH somapacitan, which is used to treat adult growth hormone insufficiency. 

North America is anticipated to account for a significant market share owing to the presence of favorable reimbursement scenarios, established healthcare infrastructure, major government initiatives, and rising healthcare awareness.

Furthermore, increasing access to novel medications due to the presence of important competitors in the region is driving the market growth in the region. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are some of the leading US-based competitors in the region, offering a wide range of human GH medicines.

Get Free Sample Report